Gene-therapy company Genprex Inc (NASDAQ:GNPX) is boosting its outreach efforts to investors with the launch of a corporate website in 2019 and new email alerts.
The new site will include presentations, stock charts, SEC filings, news, media coverage and tailored email newsletters.
As part of this roll-out, investors already can receive news regarding Genprex in their inboxes by signing up for the company’s communication list here.
On top of its investor relations push, Genprex will also be forging partnerships with media relations and public relations firms to get its message out.
“We’re extremely excited about the added emphasis on investor communications and relations in the new year,” said Genprex CEO Rodney Varner in a statement. “With the new website and email newsletters we will be launching, we intend to provide to current and potential investors unprecedented insight into what is happening at
Based in Austin, Texas, Genprex is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.
In August, Genprex entered into a collaboration with The University of Texas MD Anderson Cancer Center to extend two option agreements between Genprex and MD Anderson pertaining to the use of TUSC2, the active agent in Oncoprex.
The company has also recently hired Jan Stephens, RN, in its Cambridge office as Genprex’s new vice-president of clinical operations. Stephens, who has more than 20 years of clinical experience in the biopharma industry, is being tasked with supporting the various clinical development programs for Oncoprex.
Genprex shares rose 7.7% to $1.26 in Wednesday’s morning trading session.